VALCYTE (valganciclovir HCl)
CMV RETINITIS IN AIDS PATIENT·+3
ROCHE
Indication
Prevention of cytomegalovirus disease after kidney-pancreas transplantation
Prevention of cytomegalovirus disease after kidney-pancreas transplantation refers to prophylactic antiviral management to avert primary infection or reactivation of human betaherpesvirus 5 in simultaneous or sequential renal and pancreatic allograft recipients. Read more about Prevention of cytomegalovirus disease after kidney-pancreas transplantation
25 drugs 23 manufacturers
Drugs that treat it
Common Prevention of cytomegalovirus disease after kidney-pancreas transplantation therapies.
VALCYTE (valganciclovir HCl)
CMV RETINITIS IN AIDS PATIENT·+3
ROCHE
VALGANCICLOVIR HCL
CMV RETINITIS IN AIDS PATIENT·+3
QUALITEST
VALGANCICLOVIR HCL
ANTIVIRAL - CMV INFECTION·CMV RETINITIS IN AIDS PATIENT·+3
DR.REDDY'S LAB
VALGANCICLOVIR HCL
ANTIVIRAL - CMV INFECTION·CMV RETINITIS IN AIDS PATIENT·+3
AHP
VALGANCICLOVIR HCL
ANTIVIRAL - CMV INFECTION·CMV RETINITIS IN AIDS PATIENT·+3
CAMBER PHARMACE
VALGANCICLOVIR HCL
ANTIVIRAL - CMV INFECTION·CMV RETINITIS IN AIDS PATIENT·+3
AUROBINDO PHARM
VALGANCICLOVIR HCL
CMV RETINITIS IN AIDS PATIENT·+3
ACTAVIS PHARMA,
VALGANCICLOVIR HCL
CMV RETINITIS IN AIDS PATIENT·+3
QUALITEST/PAR P
Filter & compare in the drug finder →Opens the drug finder with Prevention of cytomegalovirus disease after kidney-pancreas transplantation preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPrevention of cytomegalovirus disease after kidney-pancreas transplantation refers to prophylactic antiviral management to avert primary infection or reactivation of human betaherpesvirus 5 in simultaneous or sequential renal and pancreatic allograft recipients.
In these immunosuppressed patients—especially high-risk donor-seropositive and recipient-seronegative cohorts—uncontrolled viral replication can progress from asymptomatic viremia to systemic CMV syndrome characterized by fever, leukopenia, and thrombocytopenia, or to invasive end-organ disease.
Manifestations may include pneumonitis, hepatitis, pancreatitis, and gastrointestinal ulceration, which significantly increase the risk of allograft rejection, graft dysfunction, opportunistic superinfections, and patient mortality.
- nih.gov
Prevention of cytomegalovirus disease after kidney-pancreas transplantation refers to prophylactic antiviral management to avert primary infection or reactivation of human betaherpesvirus 5 in simultaneous or sequential renal and pancreatic allograft recipients In these immunosuppressed patients—especially high-risk donor-seropositive and recipient-seronegative cohorts—uncontrolled viral replication can progress from asymptomatic viremia to systemic CMV syndrome characterized by fever, leukopeni...
- frontiersin.org
Prevention of cytomegalovirus disease after kidney-pancreas transplantation refers to prophylactic antiviral management to avert primary infection or reactivation of human betaherpesvirus 5 in simultaneous or sequential renal and pancreatic allograft recipients In these immunosuppressed patients—especially high-risk donor-seropositive and recipient-seronegative cohorts—uncontrolled viral replication can progress from asymptomatic viremia to systemic CMV syndrome characterized by fever, leukopeni...
- nih.gov
Prevention of cytomegalovirus disease after kidney-pancreas transplantation refers to prophylactic antiviral management to avert primary infection or reactivation of human betaherpesvirus 5 in simultaneous or sequential renal and pancreatic allograft recipients
- contagionlive.com
In these immunosuppressed patients—especially high-risk donor-seropositive and recipient-seronegative cohorts—uncontrolled viral replication can progress from asymptomatic viremia to systemic CMV syndrome characterized by fever, leukopenia, and thrombocytopenia, or to invasive end-organ disease
- ovid.com
Manifestations may include pneumonitis, hepatitis, pancreatitis, and gastrointestinal ulceration, which significantly increase the risk of allograft rejection, graft dysfunction, opportunistic superinfections, and patient mortality
- ovid.com
Manifestations may include pneumonitis, hepatitis, pancreatitis, and gastrointestinal ulceration, which significantly increase the risk of allograft rejection, graft dysfunction, opportunistic superinfections, and patient mortality
- fiercepharma.com
Manifestations may include pneumonitis, hepatitis, pancreatitis, and gastrointestinal ulceration, which significantly increase the risk of allograft rejection, graft dysfunction, opportunistic superinfections, and patient mortality
Personalize your experience
Follow Prevention of cytomegalovirus disease after kidney-pancreas transplantation and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.